Legato Capital Management LLC Lowers Holdings in Krystal Biotech, Inc. $KRYS

Legato Capital Management LLC decreased its position in Krystal Biotech, Inc. (NASDAQ:KRYS) by 49.1% during the fourth quarter, HoldingsChannel.com reports. The firm owned 1,913 shares of the company’s stock after selling 1,844 shares during the quarter. Legato Capital Management LLC’s holdings in Krystal Biotech were worth $472,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of KRYS. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% in the 1st quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock worth $294,000 after purchasing an additional 964 shares in the last quarter. AQR Capital Management LLC boosted its stake in Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock worth $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Krystal Biotech by 4.5% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock worth $2,870,000 after purchasing an additional 688 shares in the last quarter. Empowered Funds LLC bought a new position in Krystal Biotech in the 1st quarter worth about $218,000. Finally, Cetera Investment Advisers boosted its stake in Krystal Biotech by 107.9% in the 2nd quarter. Cetera Investment Advisers now owns 4,344 shares of the company’s stock worth $597,000 after purchasing an additional 2,255 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on KRYS. Guggenheim upped their price target on shares of Krystal Biotech from $224.00 to $284.00 and gave the stock a “buy” rating in a research note on Wednesday, February 25th. HC Wainwright reiterated a “buy” rating and issued a $310.00 price target on shares of Krystal Biotech in a research note on Monday, May 18th. Chardan Capital upped their price target on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Evercore reiterated an “outperform” rating and issued a $300.00 price target on shares of Krystal Biotech in a research note on Tuesday, May 5th. Finally, The Goldman Sachs Group upped their price target on shares of Krystal Biotech from $206.00 to $327.00 and gave the stock a “buy” rating in a research note on Friday, January 30th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $324.11.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of Krystal Biotech stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Kathryn Romano sold 750 shares of Krystal Biotech stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $267.60, for a total value of $200,700.00. Following the completion of the sale, the chief accounting officer owned 22,366 shares of the company’s stock, valued at $5,985,141.60. The trade was a 3.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 38,195 shares of company stock valued at $10,227,642 over the last quarter. Corporate insiders own 13.10% of the company’s stock.

Krystal Biotech Stock Performance

NASDAQ KRYS opened at $306.63 on Thursday. Krystal Biotech, Inc. has a one year low of $123.03 and a one year high of $319.48. The stock has a 50-day moving average of $275.34 and a 200 day moving average of $259.63. The company has a market capitalization of $9.04 billion, a price-to-earnings ratio of 40.99 and a beta of 0.50.

Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, May 4th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The company had revenue of $116.36 million during the quarter, compared to the consensus estimate of $112.11 million. On average, equities analysts predict that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Krystal Biotech Company Profile

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.